keyword
https://read.qxmd.com/read/38761297/emerging-medications-and-strategies-in-acute-pain-management-evolving-role-of-novel-sodium-and-calcium-channel-blockers-peptide-based-pharmacologic-drugs-and-non-medicinal-methods
#1
REVIEW
Alan D Kaye, Driskell R Greene, Catherine Nguyen, Amanda Ragland, Mason P Granger, William Peyton Wilhite, Kylie Dufrene, Sahar Shekoohi, Christopher L Robinson
PURPOSE OF REVIEW: The present investigation evaluated integration of novel medication technology to enhance treatment options, while improving patient outcomes in acute pain management. In this regard, we focused on determining the role of development and utilization of cutting-edge pharmaceutical advancements, such as targeted drug delivery systems, as well as non-pharmacologic interventions in addressing acute pain states. Further research in this area is warranted related to the need for increased patient comfort and reduced adverse effects...
May 18, 2024: Current Pain and Headache Reports
https://read.qxmd.com/read/38761162/emerging-drugs-for-the-treatment-of-short-bowel-syndrome
#2
REVIEW
Tristan Frau, Myriam El Khatib, Brune De Dreuille, Lore Billiauws, Alexandre Nuzzo, Francisca Joly
INTRODUCTION: SBS is a rare and disablingcondition. The standard management is based on diet optimization withparenteral supplementation. In addition, glucagon-like peptide-2 (GLP-2)analogs, have shown promising results as disease-modifying therapies for SBS. AREAS COVERED: Short bowel syndrome (SBS) isdefined as a reduction in functional intestinal length to less than 200 cm,leading to intestinal failure (IF) leading to malnutrition and parenteralsupport dependency...
May 18, 2024: Expert Opinion on Emerging Drugs
https://read.qxmd.com/read/38760804/scarlet-supplemental-citicoline-administration-to-reduce-lung-injury-efficacy-trial-study-protocol-for-a-single-site-double-blinded-placebo-controlled-and-randomized-phase-1-2-trial-of-i-v-citicoline-cdp-choline-in-hospitalized-sars-cov-2-infected-patients
#3
JOURNAL ARTICLE
Sonal Pannu, Matthew C Exline, Joseph S Bednash, Joshua A Englert, Philip Diaz, Amy Bartlett, Guy Brock, Qing Wu, Ian C Davis, Elliott D Crouser
BACKGROUND: The SARS CoV-2 pandemic has resulted in more than 1.1 million deaths in the USA alone. Therapeutic options for critically ill patients with COVID-19 are limited. Prior studies showed that post-infection treatment of influenza A virus-infected mice with the liponucleotide CDP-choline, which is an essential precursor for de novo phosphatidylcholine synthesis, improved gas exchange and reduced pulmonary inflammation without altering viral replication. In unpublished studies, we found that treatment of SARS CoV-2-infected K18-hACE2-transgenic mice with CDP-choline prevented development of hypoxemia...
May 18, 2024: Trials
https://read.qxmd.com/read/38758736/praziquantel-related-visual-disorders-among-recipients-in-mass-drug-administration-campaigns-in-schistosomiasis-endemic-settings-systematic-review-and-meta-analysis-protocol
#4
JOURNAL ARTICLE
Anthony Danso-Appiah, David Owiredu, Kwadwo Owusu Akuffo
BACKGROUND: Hundreds of millions of doses of Praziquantel (PZQ) have been administered to persons with and without schistosomiasis living in schistosomiasis endemic settings, through the mass drug administration (MDA) strategy which started in the early 2000s. A recent publication suggested high risk of PZQ-related visual disorders, raising public health concerns. We aim to systematically synthesize evidence on the magnitude of PZQ-related visual disorders. METHODS: We will search PubMed, Google Scholar, CINAHL, SCOPUS, CENTRAL and LILACS from 1977 (when the first human clinical trials on PZQ started) to 31st May 2024, with no language restrictions...
2024: PloS One
https://read.qxmd.com/read/38758222/cosmeceuticals-for-antiaging-a-systematic-review-of-safety-and-efficacy
#5
REVIEW
Megan Lau, Jessica Mineroff Gollogly, Jennifer Y Wang, Jared Jagdeo
Cosmeceuticals, the bridge between pharmaceuticals and cosmetics, contain biologically active ingredients that may improve the skin's overall appearance. As the market, accessibility, and popularity of cosmeceuticals increase, it is essential to understand the safety and efficacy of such products. This systematic review aims to examine published clinical studies involving the use of cosmeceuticals for antiaging to provide evidence-based recommendations based on available efficacy and safety data. PubMed, Embase, and Cochrane were systematically searched on January 1, 2023 using PRISMA guidelines...
May 17, 2024: Archives of Dermatological Research
https://read.qxmd.com/read/38758099/cost-effectiveness-of-empagliflozin-as-add-on-to-standard-of-care-for-chronic-kidney-disease-management-in-the-united-kingdom
#6
JOURNAL ARTICLE
Mafalda Ramos, Laetitia Gerlier, Anastasia Uster, Louise Muttram, Andrew H Frankel, Mark Lamotte
OBJECTIVE: The sodium-glucose co-transporter-2 inhibitor empagliflozin was approved for treatment of adults with chronic kidney disease (CKD) on the basis of its demonstrated ability to slow CKD progression and reduce the risk of cardiovascular death. This analysis was performed to assess the cost effectiveness of empagliflozin plus standard of care (SoC) versus SoC alone in the treatment of CKD in the UK. METHODS: A comprehensive, patient-level CKD progression model that simulates the evolution of risk factors for disease progression based on CKD-specific equations and clinical data was used to project a broad range of CKD-related complications...
May 17, 2024: Journal of Medical Economics
https://read.qxmd.com/read/38757325/maximizing-isrib-potential-requires-addressing-specificity-long-term-safety-and-disease-specific-considerations
#7
JOURNAL ARTICLE
Alberto Boretti, Bimal Banik
BACKGROUND: Integrated Stress Response Inhibitor (ISRIB) works by inhibiting the integrated stress response, a cellular pathway involved in the regulation of protein synthesis during stress conditions. Conditions that have been studied or suggested as potential candidates for treatment with ISRIB include neurological and metabolic disorders, cognitive impairment, viral infections, and cancer. OBJECTIVE: The study aimed to discuss the challenges related to specificity, long-term safety, and disease-specific considerations crucial for realizing the full potential of ISRIB...
May 16, 2024: Current Medicinal Chemistry
https://read.qxmd.com/read/38757259/association-of-drug-therapy-with-the-risk-of-incident-frailty-a-systematic-review
#8
JOURNAL ARTICLE
Saran Thanapluetiwong, Tanchanok Chattaris, Sandra Miao Shi, Chan Mi Park, Stephanie Denise M Sison, Dae Hyun Kim
Medication is a potential factor influencing frailty. However, the relationship between pharmaceutical treatments and frailty remains unclear. Therefore, we conducted the present systematic review to summarize the association between drug therapy and the risk of incident frailty in older adults. We systematically searched the MEDLINE electronic database for articles indexed between January 1, 2000, and December 31, 2021, for randomized controlled trials (RCTs) and cohort studies reporting frailty changes associated with drug therapy...
May 17, 2024: Annals of geriatric medicine and research
https://read.qxmd.com/read/38756153/landscape-of-cancer-clinical-trials-in-india-a-comprehensive-analysis-of-the-clinical-trial-registry-india
#9
JOURNAL ARTICLE
Peng Gao, Justin Chen, Zhongyu Hong, Marcus Choi, Allison Morgan, Anton Petushkov, Rajuli Lall, Chao Liu, Vamshi K Muddu, Venugopal Arroju, Chinnababu Sunkavalli, Geoffrey Kim, Bobby Y Reddy
BACKGROUND: Cancer is one of the leading causes of morbidity and mortality in India. Clinical trials are critical for driving innovation in cancer therapy, diagnosis, and prevention. This study aims to depict the evolving landscape of cancer clinical trials in India by analysing the clinical trials registered in Clinical Trial Registry-India (CTRI). METHODS: We identified cancer trials registered in CTRI (between 2007 and 2021) using search terms adapted from the cancer types defined by the National Cancer Institute (USA)...
May 2024: Lancet Reg Health Southeast Asia
https://read.qxmd.com/read/38754593/effect-of-electrospun-poly-l-lactide-co-caprolactone-and-formulated-porcine-fibrinogen-for-diabetic-foot-ulcers
#10
JOURNAL ARTICLE
Guili Wang, Xiaoyan Li, Shuai Ju, Yao Li, Wenqiang Li, Hongbing He, Yunmin Cai, Zhihui Dong, Weiguo Fu
Diabetic foot ulcers were a significant complication of diabetes and were accompanied by delayed wound healing. To compare the effect of topical application electrospun poly (L-lactide-co-caprolactone) and formulated porcine fibrinogen (PLCL/Fg) dressing with alginate dressing when treating diabetic foot ulcers (DFUs). A single-center, prospective, randomized, patient-blinded clinical trial was conducted from July 1, 2023, to December 26, 2023. The clinical trial registration was completed on August 28, 2023 (ClinicalTrials...
May 14, 2024: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38754524/enhancing-cancer-immunotherapy-exploring-strategies-to-target-the-pd-1-pd-l1-axis-and-analyzing-the-associated-patent-regulatory-and-clinical-trial-landscape
#11
REVIEW
S S Kirthiga Devi, Sidhartha Singh, Ramesh Joga, Sharvari Y Patil, Vakalapudi Meghana Devi, Sabnis Chetan Dushantrao, Falguni Dwivedi, Gautam Kumar, Deepak Kumar Jindal, Charan Singh, Isha Dhamija, Sandeep Kumar
Cancer treatment modalities and their progression is guided by the specifics of cancer, including its type and site of localization. Surgery, radiation, and chemotherapy are the most often used conventional treatments. Conversely, emerging treatment techniques include immunotherapy, hormone therapy, anti-angiogenic therapy, dendritic cell-based immunotherapy, and stem cell therapy. Immune checkpoint inhibitors' anticancer properties have drawn considerable attention in recent studies in the cancer research domain...
May 14, 2024: European Journal of Pharmaceutics and Biopharmaceutics
https://read.qxmd.com/read/38753541/hematological-toxicity-of-cyclin-dependent-kinase-4-6-inhibitors-in-patients-with-breast-cancer-a-network-meta-analysis-and-pharmacovigilance-study
#12
REVIEW
Haiying Ding, Weiben Xu, Mengfei Dai, Shujing Li, Wenxiu Xin, Yinghui Tong, Chaoneng He, Xiufang Mi, Zhajun Zhan, Luo Fang
OBJECTIVES: We aimed to evaluate and compare the risk of hematological adverse events (AEs) associated with CDK4/6 inhibitors using data from randomized controlled trials (RCTs) and Food and Drug Adverse Event Reporting System (FAERS) database. METHODS: The PubMed, Embase, and Cochrane Library databases were searched for RCTs related to abemaciclib, palbociclib, and ribociclib. A network meta-analysis (NMA) was conducted to compare the risks of hematological AEs, and a disproportionality analysis was performed to detect signals of hematological AEs...
May 16, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38753077/preliminary-feasibility-assessment-of-a-targeted-pharmacist-led-intervention-for-older-adults-with-polypharmacy-a-mixed-methods-study
#13
JOURNAL ARTICLE
Lisheng Liu, Bernadette Brokenshire, Deborah Davies, Jeff Harrison
BACKGROUND: Polypharmacy is associated with the prescription of inappropriate medications and avoidable medication-related harm. A novel pharmacist-led intervention aims to identify and resolve inappropriate medication prescriptions in older adults with polypharmacy. AIM: To conduct a preliminary feasibility assessment of the intervention in primary care, testing whether specific components of the intervention procedures and processes can be executed as intended...
May 16, 2024: International Journal of Clinical Pharmacy
https://read.qxmd.com/read/38752645/research-progress-of-natural-products-with-the-activity-of-anti-nonalcoholic-steatohepatitis
#14
JOURNAL ARTICLE
Rui Wang, Yuheng Mao, Chunping Yu, Zhenji Rong, Ruyue Wang, Yixin Wang, Linjin Lv, Yang Gao, Zhigang Wang, Hailong Zhang
Nonalcoholic steatohepatitis (NASH), a multi-target disease, is becoming a global epidemic. Although several anti-NASH drug candidates are being evaluated in late-stage clinical trials, none have been approved by the FDA to date. Given the global prevalence of the disease, the lack of effective drugs, and the very limited therapeutic efficacy of most of the existing synthetic drugs focusing on a single target, there is an urgent need to continue to develop new therapeutic agents. In contrast, many natural products, including pure compounds and crude extracts, possess hepatoprotective activities...
May 15, 2024: Mini Reviews in Medicinal Chemistry
https://read.qxmd.com/read/38752641/qbd-assisted-development-of-a-compartment-and-sequential-drug-delivery-system-for-periodontotherapy
#15
JOURNAL ARTICLE
Pooja Jain, Zeenat Iqbal
Periodontitis, the burgeoning disease, is at an alarming stage. Although this has triggered dedicated research in this area, as the disease itself demands a multi-component therapy, there is an unmet need for a compartment and sequential drug delivery system to ameliorate disease symptoms completely. The hypothesized work consists of multitherapeutic agents such as an antibiotic, a COX-II inhibitor, an MMP inhibitor, and a bone regenerating agent in an insitu gel. However, for the development of the system, as mentioned above, a thorough investigation at each stage is necessary; therefore, the quality-by-design approach was adopted...
May 15, 2024: Combinatorial Chemistry & High Throughput Screening
https://read.qxmd.com/read/38752593/glial-modulators-as-novel-therapeutics-for-comorbid-pain-and-opioid-use-disorder
#16
REVIEW
Elizabeth K C Schwartz, Joao P De Aquino, Mehmet Sofuoglu
Chronic pain and opioid use disorder (OUD) are major public health problems, with rising opioid-related overdose deaths linked to increased opioid prescriptions for pain management. Novel treatment approaches for these commonly comorbid disorders are needed. Growing evidence supports a role for glial activation for both chronic pain and substance use disorders, including OUD. This review provides an overview of glial modulators as a novel treatment approach for comorbid pain and OUD. We aim to synthesize clinical studies investigating the efficacy of glial modulators in treating these comorbid disorders...
May 16, 2024: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/38752447/the-impacts-of-undetected-nonadherence-in-phase-ii-iii-and-post-marketing-clinical-trials-an-overview
#17
JOURNAL ARTICLE
Elise Le Flohic, Bernard Vrijens, Mickaël Hiligsmann
AIMS: This research aims to provide an overview of the consequences of undiagnosed nonadherence (noninitiation, suboptimal implementation, nonpersistence) in randomized clinical trials (RCTs). METHODS: This research was conducted by combining a literature review and qualitative semistructured interviews with key opinion leaders. Based on this groundwork, the consequences of undiagnosed nonadherence in RCTs were summarized and reported in a figure. This study focused on phases II, III and post-marketing in ambulatory settings across a variety of therapeutic areas and indications...
May 16, 2024: British Journal of Clinical Pharmacology
https://read.qxmd.com/read/38751415/a-qualitative-investigation-of-the-montgomery-%C3%A3-sberg-depression-rating-scale-discrepancies-in-rater-perceptions-and-data-trends-in-remote-assessments-of-rapid-acting-antidepressants-in-treatment-resistant-depression
#18
JOURNAL ARTICLE
Gianna Capodilupo, Raymond Blattner, Anita Must, Silvia Gamazo Navarro, Mark Opler
INTRODUCTION: Despite the development of many successful pharmaceutical interventions, a significant subset of patients experience treatment-resistant depression (TRD). Ketamine and its derivatives constitute a novel therapeutic approach to treat TRD; however, standard tools, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) are still being used to measure symptoms and track changes. METHODS: The aim of this study was to review item-level differences between rate of data change (MADRS score) and rater-weighted perception of the most useful items for assessing change in symptoms while remotely conducting the 10-item version of the MADRS in TRD in a clinical trial of rapid-acting antidepressants...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38751378/the-dark-side-of-drug-repurposing-from-clinical-trial-challenges-to-antimicrobial-resistance-analysis-based-on-three-major-fields
#19
REVIEW
Iyad Y Natsheh, Majd M Alsaleh, Ahmad K Alkhawaldeh, Duaa K Albadawi, Maisa' M Darwish, Mohammed Jamal A Shammout
Drug repurposing is a strategic endeavor that entails the identification of novel therapeutic applications for pharmaceuticals that are already available in the market. Despite the advantageous nature of implementing this particular strategy owing to its cost-effectiveness and efficiency in reducing the time required for the drug discovery process, it is essential to bear in mind that there are various factors that must be meticulously considered and taken into account. Up to this point, there has been a noticeable absence of comprehensive analyses that shed light on the limitations of repurposing drugs...
2024: Drug Target Insights
https://read.qxmd.com/read/38750981/antibody-drug-conjugates-a-promising-breakthrough-in-cancer-therapy
#20
REVIEW
Swapnali Parit, Ajit Manchare, Amol D Gholap, Prashant Munde, Navnath Hatvate, Satish Rojekar, Vandana Patravale
Antibody-drug conjugates (ADCs) provide effective cancer treatment through the selective delivery of cytotoxic payloads to the cancer cells. They offer unparalleled precision and specificity in directing drugs to cancer cells while minimizing off-target effects. Despite several advantages, there is a requirement for innovations in the molecular design of ADC owing to drug resistance, cancer heterogeneity along the adverse effects of treatment. The review critically analyses ADC function mechanisms, unraveling the intricate interplay between antibodies, linkers, and payloads in facilitating targeted drug delivery to cancer cells...
May 13, 2024: International Journal of Pharmaceutics
keyword
keyword
93344
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.